Answers are grounded in this paper and cite their sources.
Background: Advanced gastric cancer patients has poor survival rate of < 20% at 5 years.We intended to evaluate the outcomes of Cisplatin and 5-Flurouracil combination chemotherapy or 5 FU alone in this setting.Objectives: In this study we analyzed the outcomes such as response rate, progression free survival (PFS) at 6 months, and toxicity profiles of 3 weekly Cisplatin and 5-Flurouracil (PF) regimen and Weekly 5-Flurouracil (5-FU) therapy in advanced gastric cancer.Subjects and Methods: The outcomes of the chemotherapeutic regimens such as intravenous infusion of Cisplatin 75mg/m2 in divided doses and 5-Flurouracil 750mg/m2 for consecutive 3 days every 21 days (Group A) and intravenous infusion of 5-Flurouracil 500mg flat dose every week for 16 weeks (Group B) in stage III/IV gastric cancer were analyzed.Baseline parameters were obtained.Results: Twenty patients for both PF and weekly 5-FU regimens were recruited.The Overall response rate of Group A and B regimen was 40% and 20% respectively.PFS at the end 6 months was 60% and 35% respectively.Median time to progression was 5 months in group A and 3.6 months in group B. Hematological toxicity and Non hematological toxicity rates were in the acceptable range in Group A. Conclusion: Three weekly Cisplatin and 5-Flurouracil could be a good regimen when the performance status of the patient is good.Weekly 5-Flurouracil gives good quality of life and this regimen can be considered when the patient is not eligible for Cisplatin and 5-Flurouracil regimen in advanced gastric cancers.
No takes yet. Share an insight, caveat, or question.
Raja et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: